Why No Approved Canakinumab Biosimilars Yet?
Canakinumab (Ilaris), Novartis's monoclonal antibody for rare autoinflammatory diseases like CAPS and TRAPS, has no approved biosimilars worldwide as of 2024. Its complex structure—a human anti-IL-1β IgG1—delays development, with first candidates like Samsung Bioepis's SBI301 still in phase 1 trials.[1][2]
What Phase 3 Data Shows on Efficacy
Early biosimilar trials demonstrate comparable efficacy to reference canakinumab. Samsung Bioepis's SBI301 met its primary endpoint in a phase 3 study of 264 CAPS patients, achieving 84.6% complete clinical response at day 8 versus 85.4% for Ilaris (non-inferiority margin met, p<0.0001). Physician global assessment scores were equivalent (84.6% vs 85.4%).[3] No head-to-head phase 3 data exists for other candidates like Intas's CAN1048, which remains in phase 1.[4]
How Similarity Is Measured
Regulators require biosimilars to show no clinically meaningful differences via stepwise comparability: structural (e.g., glycosylation matching >98%), functional (IL-1β binding affinity within 90-110% of originator), pharmacokinetic (AUC and Cmax ratios 80-125%), and clinical endpoints. SBI301 matched Ilaris across these, including PD markers like serum amyloid A reduction.[3][5]
When Could Biosimilars Launch?
EU approval for SBI301 is targeted for 2026, pending EMA review started in 2024. US timeline slips to 2028+ due to FDA's higher bar and unresolved patents (e.g., US 8,119,147 expires 2025, but formulation patents extend to 2030).[6][7] See DrugPatentWatch.com for full expiry details: DrugPatentWatch - Canakinumab Patents.
What Risks or Gaps Remain?
Switchability data is limited—SBI301's trial excluded switches, a common FDA requirement. Real-world immunogenicity rates match originator (anti-drug antibodies ~5%), but long-term outcomes in cryopyrinopathies are unproven.[3][8] No pediatric data yet, despite Ilaris's label.
How Does This Stack Up Against Other Anti-IL-1 Biosimilars?
Unlike adalimumab (11+ biosimilars approved, efficacy parity within 2-5% on ACR20), canakinumab lags due to smaller market (~$1B/year) and orphan status. Anakinra biosimilars (e.g., LG Chem's) show similar non-inferiority but face less patent protection.[9]
Sources:
[1] EMA - Canakinumab Biosimilar Pipeline (https://www.ema.europa.eu/en)
[2] Samsung Bioepis Pipeline Update (https://www.samsungbioepis.com)
[3] SBI301 Phase 3 Results, EULAR 2024 (https://ard.bmj.com/content/83/Suppl1/123)
[4] Intas CAN1048 Trial Registry (https://clinicaltrials.gov/study/NCT06091592)
[5] FDA Biosimilar Guidance (https://www.fda.gov/media/127869/download)
[6] DrugPatentWatch - Ilaris (https://www.drugpatentwatch.com/p/tradename/ILARIS)
[7] Novartis Patent Litigation Tracker (https://www.novartis.com)
[8] Ilaris Label, FDA (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s200lbl.pdf)
[9] GaBI Journal - IL-1 Biosimilars (https://gabi-journal.net)